Binary to ternary drug–drug molecular adducts of the antihypertensive drug ketanserin (KTS) with advanced physicochemical properties
Chemical Communications · 2023
DOI: 10.1039/d2cc06666a ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Communications, 2023. Verfasst von Smruti Rekha Rout und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Industrial and Engineering Chemistry, Institute of Chemical Technology-Indian Oil Bhubaneswar Campus, Bhubaneswar, India. r.dandela@ioc…. Hauptthemen laut MEDLINE: Antihypertensive Agents, Salts. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Science and Engineering Research Board.
Abstract (Originalsprache)
Focusing on a reliable supramolecular synthon approach, novel binary and ternary molecular adducts of the antihypertensive drug ketanserin (KTS) with diverse aromatic carboxylic acid derivatives are reported.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Industrial and Engineering Chemistry, Institute of Chemical Technology-Indian Oil Bhubaneswar Campus, Bhubaneswar, India. r.dandela@iocb.ictmumbai.edu.in.
Förderung
- Science and Engineering Research Board
Zitieren
APA
Rout, S. R., Kenguva, G., Giri, L., Kar, A., & Dandela, R. (2023). Binary to ternary drug–drug molecular adducts of the antihypertensive drug ketanserin (KTS) with advanced physicochemical properties. Chemical Communications. https://doi.org/10.1039/d2cc06666a
Vancouver
Rout SR, Kenguva G, Giri L, Kar A, Dandela R. Binary to ternary drug–drug molecular adducts of the antihypertensive drug ketanserin (KTS) with advanced physicochemical properties. Chemical Communications. 2023. doi:10.1039/d2cc06666a
BibTeX
@article{Rout2023,
author = {Rout, Smruti Rekha and Kenguva, Gowtham and Giri, Lopamudra and Kar, Ananya and Dandela, Rambabu},
title = {Binary to ternary drug–drug molecular adducts of the antihypertensive drug ketanserin (KTS) with advanced physicochemical properties},
journal = {Chemical Communications},
year = {2023},
doi = {10.1039/d2cc06666a}
}
EUVIMED